CD4 and tuberculosis: The secondary endpoints included HIV viral load and immune response to ART (change in CD4 count) at 48 weeks, adverse events attributed to TB associated IRIS at 48 weeks, and other serious adverse events at 48 weeks (Grade 3 or 4 Clinical Events or Laboratory Abnormalities).